-
Kingsley affiliate Legend has again released CAR-T clinical data with a total remission rate of 97 percent, and researchers expect to use it for more front-line treatments
Time of Update: 2020-12-15
Sidaki Oronse is a new class 1 drug used in the treatment of bio-products by Legendary Bios, a chime antigen-treated T-cell (CAR-T) therapy, and a number of clinical studies are currently under way to treat patients with relapsed or refractic multiple myeloma and more front-line patients, consisting of two single-domain antibodies targeting BCMA with a differentiated structure of CAR-T.
-
Eur J Heart Fail: Relationship between roomic tatroidal hyperthroidation, laboratory early arrest, and mortality in patients with lung, colon, or pancreatic cancer
Time of Update: 2020-12-14
, the number of laboratory-based early fights (PVC) in cancer patients did not increase within 24 hours compared to the control group (median was 4 vs.
-
Multi-kinase inhibitor ON 123300 to treat relapsed/refractive advanced cancer: Upcoming Phase I clinical studies
Time of Update: 2020-12-14
Fruchtman said, "ON 123300, based on its novel mechanism of work, provides an innovative way to study advanced cancer, including patients with HR-HER2-metastassic breast cancer who have developed resistance to CDK4/6 inhibitors.
-
Ann Surg: Liver transplantation provides a longer total lifetime for colorectal cancer patients with non-removable liver metastasis
Time of Update: 2020-12-14
forward-looking (SECA-II) study aims to assess the total and disease-free survival of some non-excisible colorectal cancer patients who receive liver transplants, the results of which were published online in Ann Surg.
results show that liver transplantation provides the longest total lifetime for colorectal cancer patients with non-removable liver metastasis.
-
After 40 years of treatment of small cell lung cancer ushered in a new program, "immune era" under the giants set off a battle
Time of Update: 2020-12-14
, the CASPIAN study is a randomized, open-labeled global multi-center Phase III clinical trial that included 805 patients with extensive stage small cell lung cancer treated with first-line treatment.
-
Br J Cancer: HOX Gene: Potential Therapeutic Target for Adrenal Corticocarcinoma
Time of Update: 2020-12-14
to understand the expression of the HOX gene and its relationship to disease by analyzing the transcriptional group data of the patient.
-
BMJ: Risk of cancer in individuals with birth defects
Time of Update: 2020-12-14
study data show that in four Nordic countries, people with chromosomal and non-chromosomal birth defects have an increased risk of developing overall cancer as adults (for people under 46 years of age).
-
From 8 PD-1/PD-L1 sales revenue in the first three quarters guess health care negotiations
Time of Update: 2020-12-14
So far, the domestic market has been listed 6 PD-1 (4 domestic, 2 imports), 2 PD-L1 (all imports), a few days ago, 8 products have announced the first three quarters of the year sales results, from their sales performance or licensing of the next health care negotiations dare to report the "floor price" snooping one or two.
-
Macrophage therapy, starting with solid tumors
Time of Update: 2020-12-14
multi-effect anti-tumor mechanism of CAR-M therapy (Source: Cancer Research) The coagulation macrophage is a highly malleable cell that adjusts its properties and functions to external stimuli.
-
Br J Haematol: After the failure of the treatment of lynadamine, recurring multiple myeloma can be treated with pomadamine plus low-dose dexamisong
Time of Update: 2020-12-14
PFS was 12.2 months (7.9 months for the previously accepted boron Zomia group).
, these results support earlier treatments based on posamamine in patients treated with RRMM, including those who are already incurable.
-
Radiology: What factors affect the progression of local tumors after liver metastatic radio frequency ablation in colorectal cancer?
Time of Update: 2020-12-14
objective Of this study, the purpose of this study is to evaluate the survival of local tumor progression (LTPFS) in CLM patients with RFA, and to establish an algorithmic clinical decision-making scheme based on clinical indicators.
-
Br J Cancer: MACROD2 Gene: Integrated Hot Gene for HPV Virus in Cervical Cancer
Time of Update: 2020-12-14
HPV integration feature distribution researchers identified different virus integration characteristics by double-capture of HPV and high-flu vehicle sequencing technology (NGS) in 272 CC patients in the BioRAIDs study .NCT02428842.
-
Lancet: Pym monoantial combination chemotherapy first-line treatment of PD-L1-positive metastasis triple negative breast cancer
Time of Update: 2020-12-14
The study was conducted at 209 medical centers in 29 countries for randomized, controlled, double-blind studies involving patients with untreated local recurrence of non-surgical or metastasis triple negative breast cancer in chemotherapy (albumin yew alcohol, yew alcohol or gissie On the basis of 200 mg of Pim monoantigen or placebo every 3 weeks, PD-L1 expression (CPS score end point of the study was no progress and total lifetime.
-
Br J Cancer: Drug resistance-related studies in patients with BRAF V600E mutant colorectal cancer
Time of Update: 2020-12-14
the study of anti-tumor activity (including optimal response and progression time and mutation characteristics) in patients and treatment groups as a cohort study focused on genetic changes in patients with BRAFV600E mutant advanced colorectal cancer treated with MAPK path pathogenic inhibitors.
-
The latest clinical advances in CRISPR/Cas9 gene editing therapy
Time of Update: 2020-12-14
CTX001 is a gene editing therapy in the study of self-study CRISPR/Cas9, which aims to increase the level of fetal hemoglobin (HbF) in red blood cells by editing hematopoietic stem cells in patients with TDT and SCD.
-
Int J Epidemiol: Trends in the incidence of central nervous system tumors in children worldwide, 1988-2012
Time of Update: 2020-12-14
Regional national researchers who included age-standardized morbidity analysis retrieved CNS tumors in the Cancer (CI5) database on five continents and assessed the age-standardized incidence of children aged 0-19 years (ASR, case/1 million), the ratio of male to female incidence (IRR) and the change in the average annualized incidence (AAPC).
-
Blood: Histoprotein deacetylase and DNA methyl transferase double inhibition can effectively treat exocytoblast lymphoma
Time of Update: 2020-12-14
in a Phase 1 trial, Lorenzo and others also found that oral 5-nitrogen cytosine (AZA) and romidesin (ROMI) were safely and effectively treated in patients with relapse/recurring (R/R) PTCL and had genealogical selective activity.
patients with T-filter assist cell (tTFH) esotypes showed higher ORR (80%) and full remission rates (67%).
-
The European Union will review Merck's lung cancer-targeted drug Tepotinib
Time of Update: 2020-12-14
Tepotinib is designed to treat advanced non-small cell lung cancer (NSCLC) in adults with the interstumin-epithortic conversion factor gene (MET) exon 14 (METex14) jump mutation.
study, the main endpoint was the objective mitigation rate of patients who were followed for at least nine months through an independent review.
-
Gene therapy gives new hope for fighting rare disease DMD? Lilly smashed $135 million into the market
Time of Update: 2020-12-14
Lilly has teamed up with gene editing company Precision BioSciences to unlock the layout of gene therapy for Duchy muscular dystrophy (DMD).
lilly is working with Precision to develop new gene therapies based on its ARCUS technology.
-
Nohui health by the domestic "cancer early screening first certificate", the industry into an accelerated period?
Time of Update: 2020-12-14
According to Nohui Health co-founder and CEO Zhu Yeqing, Chang Weiqing after 7 years of research and development, invested more than 100 million U.S. dollars, and completed China's first forward-looking, large-scale, multi-center cancer early screening registered clinical trial "Clear-C", and finally won the first certificate of china's cancer early screening.
